Product category:
Laboratory and scientific books and publishing
News Release from: Frost and Sullivan | Subject: D363
Edited by the Laboratorytalk Editorial
Team on 21 December 2005
European advances in nucleic acid
technologies
Expiry of polymerase chain reaction patent offers exciting growth opportunities for nucleic acid purification and amplification technologies, says this analyst's report
The most widely used nucleic amplification technologies (Nats) are based on polymerase chain reaction (PCR), whose foundational patents expired in the USA in March 2005; patent expiry is expected to unlock considerable market opportunities Smaller companies entering the lucrative clinical kits market may offer tests without developing a novel nucleic acid technology, which will normally require heavy R and D investment
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
"PCR patent expiry would have a profound impact in the academic research kits market which is highly price sensitive.
"This segment will see enhanced competition from cheaper products," says Technical Insights industry analyst S Ravi Shankar.
"Patent expiry will also lead to a rise in competition to reduce the PCR reagent cost and instrumentation".
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
Banking on blood
The blood banking devices market will continue to post steady figures, aided by the industry's flexibility and adaptability to changing market needs and technological advancements
Despite the patent expiry that is likely to increase demand for Nat technology, the dampener lies in the persistent popularity of traditional nucleic acid separation methods such as plasmid isolation.
Due to consumer indifference, less common nucleic acid isolation techniques such as genomic deoxyribonucleic acid (DNA) from fungi have experienced a lesser degree of commercial product penetration.
Furthermore, as the number of organisms researched increases exponentially, manufacturers are not able to keep up with product line diversity, thus continuing the research community's reliance on traditional nucleic acid separation methods, such as phenol-chloroform extraction.
Moreover, end users are sceptical about making capital investments in robotics.
Also, with funding resources becoming scarcer, researchers are looking for viable alternatives to meet their growing need for inexpensive sample preparation.
Most automated sample preparation instrumentation products cost more than US$70,000, inhibiting widespread adoption of this technology.
Although most academic budgets can cover this cost, maintenance contracts and consumable/reagent costs also need to be considered.
For research programmes that only occasionally have large numbers of samples to process, the cost of labour regularly proves to be too low to justify the purchase of an instrument dedicated to sample preparation.
To address the need for flexible solutions, many manufacturers are offering products that can also manage a number of liquid-handling tasks, such as aliquoting reagents and composing reaction mixtures.
Despite daunting challenges such as funding reallocation and popularity of plasmid isolation, the future of this technology is secure because of the intrinsic paradigm shift in research.
As the scientific community transitions from sequencing to functional genomics, there will be a greater need for consistently pure nucleic acid samples, which will drive demand for automated instrumentation products.
Automated sample processing instrumentation is invaluable when handling a large number of samples, as exemplified by large-scale cloning and sequencing centres.
"Through the development of more sophisticated systems, the time currently spent on manual sample preparation and detection could be significantly reduced," explains Shankar.
"A major trend in instrumentation systems is an increase in the number of manufacturers that are focusing on low-throughput isolation instrumentation".
Low-throughput products are ideal for clinical laboratories where space and time are limited, but quality is essential.
In Europe, there is a move towards the smaller and medium throughput instruments.
This is due to more European countries operating smaller and medium-sized laboratories, which do not process as large a number of samples as those in the United States.
The demand for nucleic acid-based amplification kits has boomed and is anticipated to continue over the next decade.
This is mainly due to the completion of the human genome project and growing interest in molecular diagnostics.
Fuelled by the rich rewards of possible patents, there has been a rush to analyse genes and their functions.
Among the amplification kits, all-in-one kits that reduce labour costs and molecular-based kits are more efficient than earlier technologies.
All-in-one kits enable even regular laboratory technicians to carry out the experiments easily.
Molecular kits also have emerged as highly attractive alternatives to serology- and immunology-based assays, due to their cost effectiveness.
Also, the need for quantitative assays due to Europe's increasing unmonitored population and EU's In Vitro Diagnostic Directive (IVDD) that requires approval will convince end users to favour commercial kits.
Overall, Nat's cost and the expected shift from genomics to proteomics may restrain the market a bit but its multiple benefits of cost-effectiveness and reduction in time as well as external factors such as EU directives and PCR patent expiry are expected to hoist this technology to new heights.
European Advances in Nucleic Acid Purification and Amplification Technologies is part of the Technical Insights Healthcare vertical subscription service and it defines key markets and applications and reports on technology drivers as well as obstacles in the way of commercial success.
It also provides a detailed overview of technological advances in development laboratories, identifies key companies and developers, and provides estimates of timelines for commercialising technology.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
